PureTech Health (LON:PRTC) Shares Down 15.2% – Time to Sell?

PureTech Health plc (LON:PRTC)’s share price fell 15.2% on Tuesday . The company traded as low as GBX 117.20 ($1.49) and last traded at GBX 117.20 ($1.49). 42,764,352 shares changed hands during mid-day trading, an increase of 2,645% from the average session volume of 1,557,904 shares. The stock had previously closed at GBX 138.20 ($1.76).

Analyst Upgrades and Downgrades

Separately, Jefferies Financial Group reiterated a “buy” rating and set a GBX 455 ($5.79) price objective on shares of PureTech Health in a research note on Monday, December 16th.

PureTech Health Trading Down 15.2 %

The stock has a market cap of £352.05 million, a PE ratio of -4.81 and a beta of 1.02. The company has a current ratio of 3.68, a quick ratio of 2.51 and a debt-to-equity ratio of 45.82. The firm has a fifty day simple moving average of GBX 139.76 and a two-hundred day simple moving average of GBX 149.53.

About PureTech Health

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.